NeuroHealing Pharmaceuticals Inc.

Internet:
info@neurohealing.com
http://www.neurohealing.com

NeuroHealing develops and commercializes novel therapeutics based on new formulation strategies to treat the needs of post-acute neurorehabilitation patients, including disorders such as traumatic brain injury, stroke, Parkinson�s disease and other motor neuron diseases.

Recent Company Headlines

• 08/26/11 - The Michael J. Fox Foundation Grants Second Award to NeuroHealing for Clinical Trial of NH004 for Sialorrhea Control in Parkinson's Disease
• 05/23/11 - NeuroHealing Announces Orphan Drug Designation in Europe for NH001 for the Treatment of Patients Following a Moderate or Severe Traumatic Brain Injury
• 05/16/11 - NeuroHealing Announces Strategic Master Services and Investment Agreement With Cato BioVentures
• 05/09/11 - NeuroHealing Announces Issuance of U.S. Patent for Brain Injury Treatment
• 12/10/10 - Positive Results of Phase II Clinical Study for the Treatment of Sialorrhea Presented at Parkinson' Disease Congress by NeuroHealing Pharmaceuticals
• 11/03/10 - NeuroHealing Awarded Qualified Therapeutic Development Project Grant
• 08/21/09 - NeuroHealing Announces Formation Of Medical Advisory Board For NH02D Program
• 04/13/09 - NeuroHealing to Present Data on NH02D Premature Ejaculation Drug at AUA Meeting
• 02/02/09 - NeuroHealing Appoints David Gwynne, Vice President Business Development
• 09/24/08 - Oct. 6-7: NeuroHealing Pharmaceuticals To Present At Drug Repositioning Summit In Boston
• 08/11/08 - Industry Leaders Select NeuroHealing's NH001 Among Top Ten Most Promising Neuroscience Projects Available For Partnering
• 07/22/08 - Life Science Angels Makes Additional Investment In NeuroHealing Pharmaceuticals
• 02/19/08 - NeuroHealing Pharmaceuticals initiates Phase II Clinical Trial of NH004 for Sialorrhea Control in Parkinson's Disease Patients
• 01/03/08 - NeuroHealing Pharmaceuticals Appoints Burt Adelman, M.D., To Board Of Directors
• 12/13/07 - The Michael J. Fox Foundation Awards Funding To NeuroHealing Pharmaceuticals Researchers for a Phase II Clinical Trial of NH004 for Sialorrhea Control in Parkinson's Disease Patients
• 03/12/07 - NeuroHealing Pharmaceuticals Presents Clinical Data For NH001 In Coma Recovery At The American Society For Experimental NeuroTherapeutics Annual Meeting
• 09/12/06 - NeuroHealing Pharmaceuticals CEO, Neal Farber, To Speak At The Dow Jones VentureWire Health Care Innovations 2006 Conference, The Biotech & Life Sciences Global Venture Congress 2006, And The Life Sciences Venture Summit 2006
• 05/25/06 - NeuroHealing Receives FDA Orphan Drug Designation For NH001 For The Treatment Of Patients In A Vegetative State Or Minimally Conscious State Following Brain Injury
• 11/03/05 - NeuroHealing Pharmaceuticals To Present At Rodman & Renshaw Techvest Seventh Annual Healthcare Conference, Nov. 8
• 08/31/05 - NeuroHealing Pharmaceuticals Announces IND Submission For NH001 To Improve The Outcome Of Patients In A Vegetative State Following A Traumatic Brain Injury
• 12/08/04 - NeuroHealing Commences Clinical Trial Of NH001 For Coma Patients

This company has no media releases.

Recent Reports and Filings